

**Fourth Annual NCI Alliance for Nanotechnology in Cancer
Investigators' Meeting
October 20-22, 2009
Manhattan Beach, California**

Agenda

Monday, October 19

12 noon – 6:00 p.m. **Poster Setup**

1:30 p.m. – 6:00 p.m. **Tutorial Sessions**

**Requirements for Introducing Nanotherapeutics to
Clinical Trials: Science to Compliance**

Mark Davis, Ph.D.
California Institute of Technology

**Clinical Therapeutics: In Vivo Molecular Imaging
Diagnostics**

Mike Phelps, Ph.D.
California Institute of Technology

**In Vitro Diagnostic Tools – Multiplexed Assays
Based on Nanotechnology**

Jim Heath, Ph.D.
California Institute of Technology

Tuesday, October 20

8:00 a.m. – 8:30 a.m. **Opening Remarks**

Welcome

Piotr Grodzinski, Ph.D., Director, NCI Alliance for
Nanotechnology in Cancer

**Nanotechnology in Cancer – In Search of the
Winning Strategy**

Anna Barker, Ph.D., Deputy Director, NCI

8:30 a.m. – 10:00 a.m. **Plenary Session**

Larry Norton, M.D.
Memorial-Sloan Kettering Cancer Center

Jim Heath, Ph.D.
California Institute of Technology

10:30 a.m. – 12:45 p.m. **Technology Commercialization Session**

BIND Targeted Nanotherapeutics

Jeff Hrkach, Ph.D.
BIND Biosciences

Carbon Nanotube X-Ray for Medical Imaging

Frank Sprenger, Ph.D.
XinRay Systems

Development of a Nanotechnology-Based PSA Assay for Earlier Diagnosis of Prostate Cancer Recurrence

James Storhoff, Ph.D.
Nanosphere, Inc.

A New Era of Therapeutic Design: PRINT® Technology as a Mechanism for Producing Rationally Design Nanoparticles for Applications in Cancer

Seth Rudnick, M.D.
Liquidia Technologies Inc.

12:45 p.m. – 2:15 p.m. Lunch

2:15 p.m. – 4:30 p.m. ***Concurrent Session I & II***

Session I: Nanotherapeutics I

Georgia Chen, Ph.D.
Emory University Winship Cancer Institute

Samuel Wickline, M.D.
Washington University in St. Louis

Roger Tsien, Ph.D.
University of California, San Diego

Mansoor Amiji, Ph.D.
Northeastern University

Miqin Zhang, Ph.D.
University of Washington

Tayyaba Hasan, Ph.D.
Harvard Medical School and Massachusetts General Hospital

Session II: Diagnostic Techniques based on Nanotechnology

C. Shad Thaxton, M.D., Ph.D.
Northwestern University

Paul Mischel, M.D.
David Geffen UCLA School of Medicine

Shan X. Wang, Ph.D.
Stanford University

Henry VanBrocklin, Ph.D.
University of California, San Francisco

Michael Heller, Ph.D.
University of California, San Diego

4:30 p.m. – 5:00 p.m.

Break

5:00 p.m. – 7:00 p.m.

Concurrent Session III & IV

Session III: Contrast Agents and Imaging Techniques

Moungi Bawendi, Ph.D.
Massachusetts Institute of Technology

Rihe Liu, Ph.D.
The University of North Carolina at Chapel Hill

Sanjiv Sam Gambhir, M.D., Ph.D.
Stanford University

Chun Li, Ph.D.
University of Texas M.D. Anderson Cancer Center

Teri Odom, Ph.D.
Northwestern University

Session IV: Nanotechnology in the Clinic

Vincent Cryns, M.D.
Northwestern University

William Zamboni, PharmD, Ph.D.
The University of North Carolina at Chapel Hill

Caius Radu, M.D.
University of California, Los Angeles

Mark E. Davis, Ph.D.
California Institute of Technology

Brian Leyland-Jones, M.D., Ph.D.
Emory University

Gregory Lanza, M.D., Ph.D.
Washington University in St. Louis

Wednesday, October 21

8:45 a.m. – 9:15 a.m. Alliance Update & Path Forward – Piotr Grodzinski, Ph.D.

9:15 a.m. - 9:45 a.m. Break

9:45 a.m. – 11:30 a.m. **Working Group Session I**

In Vitro Diagnostics
Discussion Leader: Shan Wang, Ph.D., Stanford University

Therapy and Post-Therapy Monitoring
Discussion Leader: Gayle Woloschak, Ph.D., Northwestern University

Informatics/Data Sharing
Discussion Leaders: Sharon Gaheen, M.B.A., SAIC-Frederick and Nathan Baker, Ph.D., Washington University in St. Louis

Communication and Integration Working Group (CIWG)
Discussion Leader: Krzysztof Ptak, Ph.D., M.B.A., NCI

11:30 a.m. – 1:00 p.m. Lunch

1:00 p.m. – 2:45 p.m. **Working Group Session II**

Imaging
Discussion Leader: Ravindra Pandey, Ph.D., University of Buffalo

Nanotechnology Tools and Fabrication

Discussion Leader: Vinayak Dravid, Ph.D.,
Northwestern University

Toxicology
Discussion Leader: Anil Patri, Ph.D., Nanotechnology
Characterization Laboratory

3:00 p.m. – 6:00 p.m. Poster Session

Thursday, October 22

8:45 a.m. – 9:30 a.m. **Plenary Session**
**Molecular Characterization of Circulating Tumor
Cells**

Daniel Haber, M.D., Ph.D.
Massachusetts General Hospital

9:45 a.m. – 12:00 p.m. **Concurrent Session V & VI**

Session V: Nanotherapeutics II

Gayle Woloschak, Ph.D.
Northwestern University

Erkki Ruoslahti, M.D., Ph.D.
Burnham Institute for Medical Research University of
California, Santa Barbara

Omid Farokhzad, M.D.
Brigham and Women's Hospital/Harvard Medical
School

Jan Schnitzer, M.D.
Proteogenomics Research Institute for Systems
Medicine (PRISM)

**Session VI: Nano Materials Characterization and
Nanoinformatics**

Wenbin Lin, Ph.D.
The University of North Carolina at Chapel Hill

Robert Sinclair, Ph.D.
Stanford University

May Dongmei Wang, Ph.D.
Georgia Institute of Technology and Emory University

David Sept, Ph.D.
Washington University in St. Louis

Anil Patri, Ph.D.
Nanotechnology Characterization Laboratory National
Cancer Institute at Frederick

Muhammad Yousaf, Ph.D.
The University of North Carolina at Chapel Hill

12:00 p.m. – 12:30 p.m. Closing Remarks/Adjourn